CapsoVision, Inc. (NASDAQ:CV) Sees Significant Increase in Short Interest

Key Points

• Short interest in CapsoVision surged 124.8% to 1,244,098 shares as of March 31, equal to 2.5% of the stock and a days-to-cover ratio of 1.5 based on average volume.
• Institutional activity showed notable accumulation: State Street increased its stake 340.7% to 85,929 shares and Geode added 34.1%, while Citadel, Millennium and Virtu each initiated new, smaller positions.
• Analyst and stock outlook is mixed — Benchmark cut its target to $10 while MarketBeat lists a consensus "Moderate Buy" and an $8.50 average target; the shares traded near $6.25, with a $311.5M market cap, a negative P/E and Q1 EPS of $0.02 on $3.92M revenue.

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,244,098 shares, a growth of 124.8% from the March 15th total of 553,348 shares. Based on an average trading volume of 815,476 shares, the days-to-cover ratio is presently 1.5 days. Currently, 2.5% of the company's stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CV. State Street Corp increased its stake in shares of CapsoVision by 340.7% during the fourth quarter. State Street Corp now owns 85,929 shares of the company's stock worth $919,000 after acquiring an additional 66,429 shares during the period. Geode Capital Management LLC increased its stake in shares of CapsoVision by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company's stock worth $1,649,000 after acquiring an additional 39,231 shares during the period. Citadel Advisors LLC purchased a new stake in CapsoVision during the third quarter worth about $115,000. Millennium Management LLC purchased a new stake in CapsoVision during the fourth quarter worth about $163,000. Finally, Virtu Financial LLC purchased a new stake in CapsoVision during the fourth quarter worth about $128,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Benchmark cut their price target on shares of CapsoVision from $14.00 to $10.00 and set a "speculative buy" rating on the stock in a research note on Friday, March 27th. Weiss Ratings restated a "sell (e)" rating on shares of CapsoVision in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of CapsoVision to a "hold" rating in a research note on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $8.50.

CapsoVision Stock Performance

NASDAQ CV traded down $0.13 during trading on Friday, reaching $6.25. The company's stock had a trading volume of 91,142 shares, compared to its average volume of 553,105. The firm has a market cap of $311.50 million and a price-to-earnings ratio of -2.85. CapsoVision has a twelve month low of $3.43 and a twelve month high of $15.37. The business's fifty day moving average price is $5.78 and its 200-day moving average price is $6.44.

CapsoVision (NASDAQ:CV - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $3.92 million for the quarter.

About CapsoVision

CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.